EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab

Markus Moehler, Harry H Yoon, Daniel-Christoph Wagner, Silu Yang, Jingwen Shi, Yun Zhang, Han Hu, Christopher La Placa, Yanyan Peng, Wenting Du, Adrienne McCampbell, Wenjie Xu und 4 weitere

Modern Pathology · 2025-09 · 38 (9) · 100793

DOI: 10.1016/j.modpat.2025.100793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025-09. Verfasst von Markus Moehler und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gastrointestinal Oncology, Johannes Gutenberg University Clinic, Mainz, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BeiGene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor Area Positivity (TAP) score is an emerging score measuring programmed death-ligand 1 (PD-L1) expression in tumors. However, the availability of concordance data between TAP score and other immunohistochemistry scoring methods is limited. We investigated concordance between TAP score and combined positive score (CPS) and the relationship between PD-L1 status and clinical outcomes using gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) and esophageal squamous cell carcinoma (ESCC) samples from patients subsequently treated with tislelizumab. Baseline tissue samples from RATIONALE-305 (GC/GEJC; NCT03777657), RATIONALE-302 (ESCC; NCT03430843), and RATIONALE-306 (ESCC; NCT03783442) were assessed for PD-L1 expression using an investigational use-only version of the VENTANA PD-L1 (SP263) CDx Assay. PD-L1 status was scored by TAP score and CPS. Concordance and correlation of both scores with clinical and safety outcomes were analyzed. Across all trials, agreement between TAP score and CPS was significant at PD-L1 cutoffs of ≥1%/≥1, ≥5%/≥5, and ≥10%/≥10 (Cohen's κ, 0.64-0.85). Similar outcomes for overall survival (OS), progression-free survival, objective response rate, and duration of response were observed between TAP score- and CPS-defined PD-L1-positive subgroups at analogous PD-L1 cutoffs. OS hazard ratios in the PD-L1-high subgroups were similar between protocol-defined TAP score and the same numeric CPS value (OS hazard ratio [95% CI]: RATIONALE-305, 0.72 [0.59-0.88] and 0.73 [0.60-0.89]; RATIONALE-302, 0.52 [0.35-0.76] and 0.54 [0.37-0.78]; and RATIONALE-306, 0.63 [0.45-0.89] and 0.58 [0.42-0.81], respectively). Safety outcomes were generally comparable between all PD-L1 subgroups. In conclusion, TAP score and CPS are clinically comparable immunohistochemistry measures of tumor PD-L1 expression in tislelizumab-treated patients with GC/GEJC or ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkers, TumorEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaStomach NeoplasmsAgedFemaleHumansMaleMiddle AgedImmunohistochemistryTreatment OutcomeClinical Trials as Topic

Stichwörter der Autor:innen

immune checkpoint inhibitorsneoplasmsprogrammed cell death 1 receptorstomach

Substanzen

Antibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkers, TumorCD274 protein, humantislelizumab

Autor:innen und Institutionen

  • Department of Internal Medicine, Gastrointestinal Oncology, Johannes Gutenberg University Clinic, Mainz, Germany.
  • Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota.
  • Institute for Pathology, Johannes Gutenberg-Universitat Mainz, Mainz, Germany.
  • Clinical Biomarker Sciences and CDx Development, BeOne Medicines, Ltd., Beijing, China.
  • Clinical Biomarker Sciences and CDx Development, BeOne Medicines, Ltd., Los Angeles, California.
  • Clinical Biomarker Sciences and CDx Development, BeOne Medicines, Ltd., Shanghai, China.

Förderung

  • BeiGene

Zitieren

APA

Moehler, M., Yoon, H. H., Wagner, D. C., Yang, S., Shi, J., Zhang, Y., Hu, H., La Placa, C., Peng, Y., Du, W., McCampbell, A., Xu, W., Shen, Z., Xu, H., Huang, R., & Kato, K. (2025). Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab. Modern Pathology, 38(9), 100793. https://doi.org/10.1016/j.modpat.2025.100793

Vancouver

Moehler M, Yoon HH, Wagner DC, Yang S, Shi J, Zhang Y, et al. Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab. Modern Pathology. 2025;38(9):100793. doi:10.1016/j.modpat.2025.100793

BibTeX
@article{Moehler2025,
  author = {Moehler, Markus and Yoon, Harry H and Wagner, Daniel-Christoph and Yang, Silu and Shi, Jingwen and Zhang, Yun and Hu, Han and La Placa, Christopher and Peng, Yanyan and Du, Wenting and McCampbell, Adrienne and Xu, Wenjie and Shen, Zhirong and Xu, Hui and Huang, Ruiqi and Kato, Ken},
  title = {Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab},
  journal = {Modern Pathology},
  year = {2025},
  volume = {38},
  number = {9},
  pages = {100793},
  doi = {10.1016/j.modpat.2025.100793}
}
Kostenlos starten →